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BACKGROUND: The current study was conducted to characterize the epidemiology, histology, and radiographic features of as well as
the surgical approach to pediatric and adolescent renal cell carcinoma (pRCC). METHODS: pRCC cases prospectively enrolled on the
Children’s Oncology Group study AREN03B2 underwent central pathology, radiology, surgery, and oncology review. RESULTS: As of
June 2012, 120 of a total of 3250 patients enrolled on AREN03B2 (3.7%) were found to have unilateral RCC (median age, 12.9 years
[range, 1.9-22.1 years]; 52.5% were female). Central review classified these as translocation morphology (56 patients), papillary (20
patients), renal medullary carcinoma (13 patients), chromophobe (4 patients), oncocytoma (1 patient), conventional clear cell (1
patient), and RCC not otherwise specified (25 patients). Lymph node (LN) involvement (N1) was found in 35 of 73 cases (47.9%) for
which LNs were sampled, including 19 of 40 cases with primary tumors measuring <7 cm (47.5%). Using a size cutoff of 1 cm, imaging
detection of LN involvement had a sensitivity of 57.14% (20 of 35 cases; 95% CI, 39.35%-73.68%) and a specificity of 94.59% (35 of 37
cases; 95% CI, 81.81%-99.34%). Distant metastases were present in 23 cases (19.2%). Initial surgery was radical nephrectomy in 88
patients (73.3%), nephron-sparing surgery in 18 patients (15.0%), and biopsy in 14 patients (11.7%). Compared with patients under-
going radical nephrectomy, those treated with nephron-sparing surgery were less likely to have LNs sampled (6 of 18 patients
[33.3%] vs 65 of 88 patients [73.9%]; P5.002). CONCLUSIONS: Translocation RCC is the most common form of pediatric and adoles-
cent RCC. Lymph node disease is common and observed among patients with small primary tumors. Imaging has a high specificity
but relatively low sensitivity for the detection of such lymph node disease. Failure to sample LNs results in incomplete staging and
potentially inadequate disease control for younger patients with RCC. Cancer 2015;121:2457-64. VC 2015 American Cancer Society.
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INTRODUCTION
Renal cell carcinoma (RCC) is the second most common renal malignancy diagnosed among pediatric and adolescent
patients (pRCC), accounting for 2% to 6% of renal cancers.1,2 In contrast to Wilms tumor, which has well-defined thera-
pies and excellent outcomes, the understanding of pRCC is limited, and treatment recommendations are based on small
retrospective case series and reports or taken from guidelines for “adult” RCC. However, over the past few years, it has
become clear that pRCC is different from the “typical” adult RCC with regard to both tumor biology and clinical behav-
ior. For example, pRCC is most commonly translocation-type, often harboring chromosomal translocations involving the
transcription factor E3 (TFE3) gene at Xp11.2 rather than clear cell RCC as typically observed in adults.2-4 A second dis-
tinguishing feature of pRCC relates to a higher incidence of regional lymph node (LN) involvement yet a potentially
more favorable prognosis when involved LNs are completely resected in the absence of distant metastases.1,3,5 However,
insights have been limited by either the small size of the reports and or a lack of centralized expert review. To our knowl-
edge to date, there has been no systematic, large, prospective series that has documented the demographic, pathological,
radiographic, or surgical approach to pRCC.
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The Children’s Oncology Group (COG) study
AREN03B2 was designed to prospectively collect biologi-
cal tissue, histologic data, radiographic imaging, and sur-
gical data to be used for the assignment of patients to a
series of therapeutic protocols, to explore novel biological
insights, and to help refine future guidelines. Using the
centrally collected and reviewed data from this prospective
study, we herein report our experience with pRCC, high-
lighting epidemiologic, histologic, radiographic, and sur-
gical insights. The impact of the data reported herein on
the management of young adult patients with RCC is also
discussed, especially as it relates to the impact of the surgi-
cal approach on obtaining LNs.
MATERIALS AND METHODS
Study Population
The COG AREN03B2 Renal Tumor Biology and Classi-
fication Study (ClinicalTrial.gov NCT00898365) classi-
fies patients with renal tumors by histology, radiological
features, stage of disease, presence of metastasis, age at di-
agnosis, congenital abnormalities and genetic cancer pre-
dispositions, and tumor weight to define eligibility for a
series of therapeutic studies. All participants provide
informed consent at participating institutions that have
had the AREN03B2 study approved by their local Institu-
tional Review Board (IRB). AREN03B2 guidelines
require LN sampling for several associated therapeutic
(Wilms tumor) trials; formal LN dissections are not rou-
tinely recommended. Data are collected regarding
patients aged<30 years with a first occurrence of any kid-
ney tumor. Enrollment on AREN03B2 is required before
the establishment of a risk assignment enabling enroll-
ment to COG renal tumor therapeutic studies. Central
review of radiological, histological, and surgical data is
completed in real time to ensure appropriate risk stratifi-
cation. For the current study, we reviewed patients en-
rolled in the COG AREN03B2 study with central
pathologic review of RCC.
Study Design
The current study is a descriptive review of the previously
described prospective clinical trial.6 Data extracted
included epidemiological/demographic data (eg, age, sex,
race, and American Joint Committee on Cancer TNM
stage [using the 6th edition]), histologic category, radio-
graphic imaging findings (laterality, size of the primary
tumor, presence and evaluation of LNs and distant meta-
static disease), initial surgical approach (biopsy, nephron-
sparing surgery [NSS] or radical nephrectomy [RN]), and
the presence or absence of surgical LN sampling. Pathol-
ogy specimens are reviewed as previously described.6
Pathology review
A full set of hematoxylin and eosin-stained slides was sub-
mitted for review. The tumors were classified based on
histology, complemented by any available immunohisto-
chemistry performed by the submitting institution or as
part of central pathology review.
Radiological methods
Institutions enrolling cases are responsible for the assess-
ment of distant metastatic disease. Central review is man-
datory for required chest and abdominal cross-sectional
imaging to determine the status of pulmonary metastasis
and synchronous renal tumors.6 For the purpose of this
report, all cross-sectional imaging was reviewed centrally
to determine the presence of enlarged (>1 cm in short
axis) retroperitoneal LNs and distant metastasis.
Surgical methods
Surgical reports were available for central review for all
cases. NSS was assigned for cases approached as partial ne-
phrectomy or tumor enucleation, whereas RN was
assigned when the affected kidney was completely
removed. The presence or absence of surgical LN sam-
pling was determined by the presence or absence of lym-
phatic tissue submitted, reviewed by both the treating
institutional pathologist and central review pathologist,
and correlated with surgical notes indicating the surgeon’s
attempt (or lack thereof) to sample LNs.
Statistical Analysis
The collected data were analyzed with nonparametric
methods. Independent continuous variables were com-
pared using a Mann-WhitneyU test and independent cat-
egorical variables were compared using a Fisher exact test.
In addition, a logistic regression model for LN status (pos-
itive vs negative) as determined by pathology was fit with
radiographically determined LN status as the predictor.
For all tests, statistical significance was set at a P<.05.
RESULTS
Epidemiology/Demographics
As of June 2012, 3250 patients had been enrolled on
AREN03B2 and of these, 122 patients (3.75%) were
found to have central pathologic confirmation of RCC.
Two cases were bilateral RCC and 120 were unilateral
RCC. The current report focuses on the 120 unilateral
cases. The median age at diagnosis was 12.9 years (range,
1.9-22.1 years) and 63 patients (52.5%) were female.
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Racial background was 63 white patients (52.5%); 42
black or African American patients (35%); 3 Asian
patients (2.5%); 1 patient who was American Indian,
Aleutian, or Eskimo (0.8%); 5 patients classified as other
(4.2%); and 6 patients with unknown race (5%). Patients
with renal medullary carcinoma (RMC) were all noted to
have sickle cell trait, and the single patient with clear cell
RCC had multiple endocrine neoplasia type 1.
Histology and Stage
Tumor histology was noted as being of translocation mor-
phology (tRCC) in 56 patients (46.7%), RCC not other-
wise specified in 25 patients (20.8%), papillary in 20
patients (16.7%), RMC in 13 patients (10.8%), chromo-
phobe in 4 patients (3.3%), oncocytoma in 1 patient
(0.8%), and clear cell in 1 patient (0.8%). Table 1 shows
TNM stage of disease for the entire cohort and for the
translocation morphology subgroup. The most common
sites of metastases at the time of diagnosis reported by the
institutions were the lung (15 patients; 12.5%), liver (7
patients; 5.8%), and bone (3 patients; 2.5%). A total of
49 patients (40.8%) failed to have LNs sampled. In sum,
48 patients (40%) presented with either lymphatic or he-
matogenous spread. By histology, 92.3% of patients with
RMC presented with stage IV disease, 62.5% of patients
with tRCC presented with stage III or IV disease, and
39.2% of patients without tRCC or RMC presented with
stage III or IV disease (P5 .00087).
Radiographic Features
Contrast-enhanced computed tomography or magnetic
resonance imaging of the abdomen was available for cen-
tral review in 118 of 120 cases. The distribution of lateral-
ity was 60 on the right and 58 on the left. Based on the
size criterion of >1 cm for enlarged LNs, 32 of 118 cases
(27.1%) were classified as having LN involvement at
imaging. The size of the primary renal tumor was <7 cm
in 12 of 32 patients who were noted to have enlarged LNs
(37.5%). Pathologic proof of LN status was available in
73 of 120 cases (60.83%), 35 of which were positive for
tumor. Imaging correctly identified 20 of 35 LNs as posi-
tive for tumor, thereby providing a sensitivity of 57.14%
(95% confidence interval [95% CI], 39.35%-73.68%).
Although the sensitivity of imaging was poor, specificity
was high (94.59% [35 of 37 cases]; 95% CI, 81.81%-
99.34%), with patients who were LN positive radiograph-
ically having an odds of being diagnosed with positive
LNs by pathology of 23.33 times (95% CI, 4.833-
112.643; P<.0001) that for patients who were LN nega-
tive radiographically. Among 40 patients whose primary
renal tumor measured <7 cm and who had histologic
assessment of LN status, LNs were positive by pathology
in 19 cases (47.5%). Of 73 sets of independent central
reviews, there was agreement between reviewers in 55
cases (75.34%) with respect to imaging and pathology
findings regarding LN status. At central review, distant
metastatic disease was noted in 23 cases (lung in 19 cases,
liver in 5 cases, mediastinal LNs in 5 cases, supraclavicular
LNs in 2 cases, bone in 2 cases, and muscle in 1 case) with
multifocal metastasis noted in 9 of 23 cases at the time of
initial presentation.
Surgical Features
The initial surgical approach was RN in 88 cases (73.3%),
NSS in 18 cases (15.0%), and biopsy or surgical resection
of metastasis in 14 cases (11.7%), 7 of which went on to
RN and 7 of which had no further definitive resection
(Table 2). Unfortunately, only 71 cases (59.2%) had sur-
gical/pathologic evaluation of the LNs, 35 of which
(49.3%) were positive for tumor histologically. At the
time of the initial surgery, patients undergoing NSS were
less likely than those undergoing RN to have LNs sampled
(6 of 18 patients [33.3%] vs 65 of 88 patients [73.9%];
P5 .002), as were patients with lower T classification
(P5 .003) (Table 3). The median age of the patients
undergoing surgical LN sampling was younger compared
TABLE 1. TNM Stage of Pediatric and Adolescent
RCC in COG Study AREN03B2
Stage Total (N5 120) Translocation (N5 56)
T classification
Tx 14 (11.6%) 4 (7.1%)
T1 40 (33.3%) 17 (30.4%)
T2 15 (12.5%) 4 (7.1%)
T3a-c 49 (40.8%) 29 (51.8%)
T4 2 (1.7%) 2 (3.6%)
N classification
N0 36 (30%) 11 (19.6%)
N1 35 (29.2%) 23 (41.1%)
Nx 49 (40.8%) 22 (39.3%)
M classification
M0a 98 (81.7%) 50 (89.3%)
M1 22 (18.3%) 6 (10.7%)
Overall TNM stage
I 35 (29.2%) 15 (26.8%)
II 11 (9.2%) 2 (3.6%)
III 43 (35.8%) 29 (51.8%)
IV 25 (20.8%) 6 (10.7%)
Unclassifiable 6 (5%) 4 (7.1%)
Abbreviations: COG, Children’s Oncology Group; RCC, renal cell
carcinoma.
a Cases without submission of a metastatic disease case report form and
without any obvious metastases on central review were presumed to have
M0 disease.
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with those who did not have LNs sampled (12.4 years vs
13.4 years; P5 .043). In addition, there was a trend to-
ward the increasing use of NSS in those patients with
masses with a lower T classification (P5 .001) (Table 4).
Primary tumor size, age, and histology, in relation to LN
status, are presented in Table 5.
DISCUSSION
pRCC represents a unique therapeutic challenge because
of its rarity and its differences from adult RCC or other
pediatric renal tumors. The results of the current study,
which to our knowledge is the first prospective and the
largest series of well-characterized pRCC tumors pub-
lished to date, provide insight into the distinctive epide-
miology, demographics, histologic heterogeneity,
biology, radiographic imaging, and surgical management.
Epidemiological and demographic data, derived
from 6 years of systematic prospective enrollment of 3250
patients with renal tumors from approximately 210 cen-
ters, confirm that 3.7% of pediatric renal cancers among
patients aged<22 years are RCC. Although patients aged
>22 years through aged 30 years were also eligible for
enrollment in the AREN03B2 study, such patients did
not accrue, most likely due to referral patterns of enrolling
institutions. There appears to be no sex predilection in
pRCC overall, although there is a slight female predomi-
nance for translocation or TFE RCC (tRCC) specifically.
Contrary to what may be suspected or reported,7 RCC
genetic cancer predisposition syndromes were not found
to be prevalent in the current study cohort except for an
expected association between RMC and sickle cell trait;
the single patient with clear cell RCC was found to have
multiple endocrine neoplasia type 1, there was 1 case of
associated congenital adrenal hyperplasia, and 1 case of
TABLE 3. Lymph Node Sampling at the Time of Ini-
tial Resection of the Renal Mass
Yes No P
No. 71 (67.0%) 35 (33.0%)
Median age (range), y 12.4 (1.9-20.3) 13.4 (3.0-22.1) .043
T classification (% within stage) .003
Tx 1 (33.3%) 2 (66.7%)
T1 18 (46.2%) 21 (53.8%)
T2 13 (76.5%) 4 (23.5%)
T3a 32 (80.0%) 8 (20.0%)
T3b 6 (100%) 0 (0%)
T3c NA NA
T4 1 (100%) 0 (0%)
Initial surgery .002
RN (% of initial RNs performed) 65 (73.9%) 23 (26.1%)
NSS (% of initial NSSs performed) 6 (33.3%) 12 (66.7%)
Abbreviations: NA, not applicable; NSS, nephron-sparing surgery; RN, radi-
cal nephrectomy.
TABLE 4. Initial Surgical Approach to Renal Mass
in Patients With Unilateral RCC
Characteristic RN (n588) NSS (n518) P
Median age (range), y 12.7 (1.9-22.1) 13.3 (3.0-18.0) .467
T classification (% in procedure) .001
Tx 1 (1.1%) 2 (11.1%)
T1 26 (29.6%) 13 (72.2%)
T2 15 (17.1%) 2 (11.1%)
T3a 39 (44.3%) 1 (5.6%)
T3b 6 (6.8%) 0 (0%)
T3c 0 (0%) 0 (0%)
T4 1 (1.1%) 0 (0%)
Abbreviations: NSS, nephron-sparing surgery; RCC, renal cell carcinoma;
RN, radical nephrectomy.
TABLE 5. Demographics Based On Lymph Node
Status
LN1 LN- LNx
Characteristic (N5 35) (N5 36) (N5 49)
Age at diagnosis, y
Range 1.9-17.8 2.44-20.3 3-22.1
Median 12.8 10.7 13.4
Mean 12.1 10.7 12.9
SD 4.3 4.3 4.4
Primary tumor size, cm
Range 0.8-19.7 2.5-16.3 4.6-8.6
Median 6.5 6.7 5.6
Mean 7.3 7.5 6.3
SD 4.2 3.8 2.1
Histology
Translocation 23 11 22
Papillary 3 12 5
Other 3 10 12
Renal medullary 6 0 7
Chromophobe 0 2 2
Clear cell 0 0 1
Oncocytoma 0 1 0
Abbreviations: 1, positive; -, negative; LN, lymph node; SD, standard
deviation.
TABLE 2. Surgical Approach to Patients With Uni-
lateral RCC in COG Study AREN03B2
Initial Procedure N5 120 (%)
RN 88 (73.3%)
NSS 18 (15.0%)
Biopsy/peripheral resection 14 (11.7%)
Definitive renal surgery
RN 95 (79.2%)
NSS 18 (15.0%)
No definitive renal surgery 7 (5.8%)
Cases with clinically or pathologically positive LNs 36 (30.0%)
Cases with LNs sampled 73 (60.8%)
Cases with pathologically evaluated positive LNs 35/73 (47.9%)
Venous tumor thrombus 7 (5.8%)
Abbreviations: COG, Children’s Oncology Group; LNs, lymph nodes; NSS,
nephron-sparing surgery; RCC, renal cell carcinoma; RN, radical
nephrectomy.
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osteopetrosis that was treated with bone marrow trans-
plant. Referral bias, which was not likely a factor in the
current study cohort, may have contributed to previous
reports suggesting that cancer predispositions are more
prevalent in patients with pediatric and adolescent RCC.7
The data from the current study suggest that clear cell
RCC in the young is vanishingly rare and when found
warrants an exploration into possible genetic risk factors.
The most common form of pRCC is tRCC,
accounting for 47% of all cases. tRCC is found in all age
groups and all races,3,4,8,9 and was first formally recog-
nized by the World Health Organization in 2004 as a dis-
tinct, typically translocation-associated, RCC with
characteristic morphology10-13 along with immunohisto-
chemical expression of TFE3 or transcription factor EB
(TFEb).14,15 TFE3 and TFEb are members of the MiTF/
TFE family, a subgroup of basic helix-loop–helix-leucine
zipper transcription factors that share homology in DNA-
binding domains.10,16,17 Cytogenetic analysis often reveal
TFE3-ASPS, TFE3-PRCC, TFEb-a or one of the less
common variant translocations, although mechanisms for
TFE upregulation are likely heterogeneous.11,18-22 Diag-
nostic challenges with TFE immunohistochemical anti-
bodies, the lack of available cytogenetics, and inconsistent
appreciation for the morphologic spectra of tRCC may
explain the variable frequencies of tRCC noted in pub-
lished adult series, ranging from 0.9% to 9%.8,9,23-28
Rates as high as 23% have been reported when focusing
on patients aged 40 years,27 and a rate of 2.4% was
reported when focusing on patients with RCC who were
aged>50 years.28
The significance of positive LNs, a common finding
among patients with tRCC with rates of 41% reported in
the younger cohort presented herein and up to 50% to
80% in older cohorts,4,29-32 is debated, with reports sug-
gesting both a favorable3,25,33 and unfavorable32 out-
come. It is possible that age may impact such clinical
behavior, pending clarification of referral patterns in med-
ical oncology reports, because more advanced patterns
have been reported in relatively older patients with
tRCC.4,32 Rates of hematogenous metastatic disease also
vary, ranging from 9% to 11% in predominantly pediatric
reports25 to 35% to 75% in select older tRCC cohorts.32
Overall, in the current pRCC series, approximately
62.5% of tRCC cases presented with TNM stage III or IV
disease.34
The medical management of unresectable tRCC is
evolving, and is most notable for objective responses
and rare durable complete remissions in pediatric,
adolescent, and adult patients treated with vascular endo-
thelial growth factor receptor tyrosine kinase inhibi-
tors.4,29-31,35-39 Although the numbers are small, reports
of anti-tRCC activity with mechanistic target of rapamy-
cin inhibitors are available.35,36 Predicated on the ration-
ale that tRCC shares a biology that is similar to that of
other TFE translocation-associated cancers such as sarco-
mas40 and a reported clinical benefit of chemotherapy for
patients with sarcomatoid RCC variants,41,42 conven-
tional chemotherapies (typically gemcitabine-based) have
been used with anecdotal response and disease stabiliza-
tion.3 Similarly, the medical management of patients with
RMC, the most aggressive variant of RCC observed in the
current series, may include gemcitabine-based, platinum-
based, or taxane-based therapy, as well as biological-based
therapy.43,44 It is hoped that expanding our understand-
ing of the biological bases of tRCC and RMC will lead to
improved targeted therapies.
The use of radiology to aid in the staging of patients
with RCC is well established in adult patients with RCC,
but to the best of our knowledge only limited data are
available regarding pRCC.25,45,46 In the current study,
the sensitivity for the radiologic determination of LN pos-
itivity was poor, missing>42% of subsequently histologi-
cally confirmed tumor LN metastases, suggesting that
imaging alone is not sufficient to rule out lymph node
involvement in patients with pRCC. A related critical
finding was the lack of LN sampling in 40.8% of cases.
The clinical relevance is compounded by the finding that
positive LNs were found in 47.5% of primary tumors
measuring <7 cm. This contrasts with adult RCC, in
which LN positivity is uncommon with smaller tumors.47
Among the 73 patients in the current study (60.8%) who
had LNs sampled, 35 (29.2% overall; 47.9% of those
with LNs sampled) had pathological evidence of LN
involvement. Failure to sample LNs was more likely in to
occur among those with a lower T classification and
patients undergoing NSS. Reasons for omitting LN sam-
pling were not collected in the AREN03B2 study,
although we noted a trend to omit sampling during NSS
(Table 3) and among patients with smaller primary
tumors (Table 5). The relatively increased predilection for
patients with tRCC to present with involved LNs, a nota-
ble finding of involved LNs in patients with small primary
tumors, the low sensitivity of imaging to detect involved
LNs, and current surgical patterns in both pediatric and
adult patients with RCC with small primary tumors in
whom regional LN dissection is often omitted collectively
present an opportunity for an improved surgical approach
to this patient population, among whom a more compul-
sive approach to LN sampling and surgical dissection
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appears to be warranted. It should be reinforced, as it has
been in children withWilms tumor, that surgical LN sam-
pling is a fundamental part of the surgery for renal tumors
in pediatric and adolescent patients. Efforts regarding
such education and quality control have led to rates of sur-
gical LN sampling of as high as 90% in the Wilms tumor
population.48 The importance of LN sampling is not
likely limited to patients aged birth to 22 years, however,
as a more aggressive approach to LN surgery might be ex-
trapolated to “young adult” patients with RCC (age <40
years), among whom tRCC remains prevalent and in
whom insensitive imaging and LN-positive disease remain
an issue even in the setting of small primary tumors. In
balance, among patients with both Wilms tumor and
RCC, it is to our knowledge unproven that a formal LN
dissection or mandating a minimum number of LNs
improves or impacts event-free or overall survival, a ques-
tion that warrants formal prospective study.
RN remained the most common initial surgical
treatment (79%) compared with NSS (15%). NSS via
partial nephrectomy is widely used in adults with small re-
nal masses.49 Given a bias for presenting more unique and
uncommon cases, there are several reports describing par-
tial nephrectomy for patients with pRCC, provided the
size and location of the tumor are amenable to such an
approach.50,51 However, as the data from the current
study indicate, RN is clearly the predominant surgical
approach. This likely reflects the finding that many of
these tumors were larger or more locally advanced, with
>65% of the cases in the current study undergoing
upfront primary tumor surgery if T2 or greater and at least
30% having positive LNs. This was noted specifically by
the statistically significant trend toward increased NSS use
among patients with a lower T classification. It is impor-
tant to stress that the role of NSS is yet to be elucidated in
this disease, and thus its use should be reserved for selected
patients in which complete resection with negative surgi-
cal margins can be obtained. Given that current adjuvant
medical therapies are not typically curative for unresected
disease, it is important that localized disease be completely
resected.1,3,52
To the best of our knowledge, the current study
represents the largest series of children and adolescents
with RCC presented to date, collected prospectively in
a systematic fashion. One inherent limitation is a lack
of treatment and survival data, which could add mea-
sure to the insights provided. This is a function of the
study design of the AREN03B2, which is a biologic
banking and risk classification study. Eligible patients
with RCC could have enrolled on COG study
AREN0321. The AREN0321 study examines the ques-
tion of whether pediatric and adolescent patients with
RCC with completely resected N1M0 disease maintain
a relatively favorable outcome without adjuvant therapy,
and further collects treatment response data and out-
come data for all enrolled patients. AREN0321 just
recently closed and the treatment and event-free and
overall survival data are not yet available. We also can-
not present any long-term outcome or renal function
data, which are particularly important in children and
adolescents with a longer life expectancy.
pRCC typically presents at an advanced stage, with
translocation morphology being the most common. LN-
positive disease is common, even among patients with
small associated primary tumors, and imaging sensitivity
for the detection of LNmetastases remains poor. In such a
context, failure to sample LNs is a significant problem,
resulting in incomplete staging and potentially impacting
long-term survival. It is important to educate surgeons
treating this population that even among patients with
tumors with a lower T classification, LN sampling is fun-
damental and should not be omitted for “younger”
patients with RCC, perhaps inclusive of young adults
managed in adult RCC clinics.
The data generated from the current study help to
lay the ground work for future studies investigating opti-
mal medical and surgical therapy for pediatric, adolescent,
and young adult patients with RCC. The COG and the
Eastern Cooperative Oncology Group have begun plan-
ning for a joint study of tRCC across all age groups. As we
work toward understanding the outcomes for LN-positive
disease, the role of adjuvant medical therapy, or the role of
aggressive surgical resection it is important that future
studies consider the upfront surgical approach for such
patients. Similarly, expanding our understanding of the
histologic and biologic heterogeneity of RCC in the
young, as well as improved imaging sensitivity for meta-
static disease, will likely improve our management, both
surgical and medical, as surgical aggressiveness is refined
and newer targeted therapies are applied.
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